story of the week
Efficacy and Safety of Abrocitinib in Adults With Moderate-to-Severe Atopic Dermatitis After Switching From Dupilumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND)
J Am Acad Dermatol 2022 Apr 15;[EPub Ahead of Print], VY Shi, T Bhutani, L Fonacier, M Deleuran, S Shumack, H Valdez, F Zhang, GL Chan, MC Cameron, NC YinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.